Ugcg - UDP-glucose ceramide glucosyltransferase Gene

Species: Rattus norvegicus

Gene Type: protein coding
Gene ID: 83626

About Ugcg

Primary_assembly 5: 74,032,978-74,065,393 forward strand.mRatBN7.2:CM026978.1

This gene has 1 transcript (splice variant), 212 orthologues and is associated with 4 phenotypes. Biased expression in Adrenal (RPKM 17.6), Spleen (RPKM 95.4) and 9 other tissues.

Summary

Enables ceramide glucosyltransferase activity. Predicted to be involved in several processes, including cornified envelope assembly; glucosylceramide biosynthetic process; and skin development. Located in Golgi membrane. Is integral component of membrane. Orthologous to human UGCG (UDP-glucose ceramide glucosyltransferase). [provided by Alliance of Genome Resources, Apr 2022]

Ugcg Products (1)

mRNA Protein Name
NM_031795.2 NP_113983.1 ceramide glucosyltransferase

Gene Ontology

  • Molecular Function
  • Cellular Component
Molecular Function GO Annotation Evidence References Source
enables ceramide glucosyltransferase activity IDA
IDA: Inferred from direct assay
10393098 RGD
Cellular Component GO Annotation Evidence References Source
located in Golgi membrane IDA
IDA: Inferred from direct assay
9867864 RGD
located in membrane IDA
IDA: Inferred from direct assay
9867864 RGD
EXP: Inferred from Experiment IDA: Inferred from direct assay IPI: Inferred from physical interaction IMP: Inferred from mutant phenotype IGI: Inferred from genetic interaction IEP: Inferred from expression pattern

Ugcg Protein Structure

Glucosylceramide_synthase

Glucosylceramide_synthase: cd02520 (50 - 279)

  • 0
  • 100
  • 200
  • 300
  • 394 a.a.
Protein Preferred Names Protein Names

ceramide glucosyltransferase

  • GCS

  • GLCT-1

  • UDP-glucose:N-acylsphingosine D-glucosyltransferase

  • UDP-glucose:ceramide glycosyltransferase

  • glucosylceramide synthase

  • glycosylceramide synthase

Related Agents

  • Clinical Phase
  • Pre-clinical Phase

Clinical Phase

Bioactive Molecules (2)
Cat. No. Product Name Effect
Purity Phase
HY-132596 Tivanisiran Inhibitor 97.48% Phase 3
HY-148100 Emapticap pegol Inhibitor 91.38% Phase 2

Pre-clinical Phase

Bioactive Molecules (3)
Cat. No. Product Name
Effect
Purity
Rare Diseases
HY-RS15419 UGCG Human Pre-designed siRNA Set A Pre-designed Set / Unkown
HY-RS15420 Ugcg Mouse Pre-designed siRNA Set A Pre-designed Set / Unkown
HY-RS15421 Ugcg Rat Pre-designed siRNA Set A Pre-designed Set / Unkown

Orthologs Information

Species Symbol Source ID
Homo sapiens Ugcg NCBI NCBI:7357